Telos Capital Management Inc. Makes New $201,000 Investment in Stryker Corporation $SYK

Telos Capital Management Inc. purchased a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 508 shares of the medical technology company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. EPG Wealth Management LLC grew its position in Stryker by 2.6% during the 2nd quarter. EPG Wealth Management LLC now owns 3,262 shares of the medical technology company’s stock worth $1,291,000 after purchasing an additional 84 shares during the period. State of Michigan Retirement System grew its position in Stryker by 0.3% during the 2nd quarter. State of Michigan Retirement System now owns 93,499 shares of the medical technology company’s stock worth $36,991,000 after purchasing an additional 300 shares during the period. iA Global Asset Management Inc. grew its position in Stryker by 12.1% during the 2nd quarter. iA Global Asset Management Inc. now owns 10,173 shares of the medical technology company’s stock worth $4,025,000 after purchasing an additional 1,100 shares during the period. Palogic Value Management L.P. grew its position in Stryker by 4.5% during the 2nd quarter. Palogic Value Management L.P. now owns 1,115 shares of the medical technology company’s stock worth $441,000 after purchasing an additional 48 shares during the period. Finally, Tredje AP fonden grew its position in Stryker by 11.1% during the 2nd quarter. Tredje AP fonden now owns 110,000 shares of the medical technology company’s stock worth $43,519,000 after purchasing an additional 11,000 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Up 0.6%

Shares of Stryker stock opened at $358.24 on Tuesday. The firm has a market capitalization of $136.96 billion, a PE ratio of 47.45, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The firm’s 50-day moving average price is $377.43 and its 200 day moving average price is $381.12. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the company posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were paid a $0.84 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.15%.

Insider Transactions at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on SYK shares. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Rothschild Redb upgraded Stryker to a “hold” rating in a research report on Thursday, September 18th. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, BTIG Research raised their target price on Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a research report on Friday. Fourteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $433.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.